Anthropic is expanding its work in AI-enabled drug discovery and development through research partnerships with six biotechnology and pharmaceutical organisations, as it explores how its AI model Claude can support multiple stages of the drug development process.
The company's life sciences team has partnered with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group over the past several months. Anthropic has also initiated its own drug discovery programmes, including research targeting rare childhood forms of muscular dystrophy.
The initiative aims to examine how AI can help address bottlenecks across the drug development lifecycle, extending beyond the commonly discussed applications of AI in designing new molecules. According to Anthropic, the process involves several interconnected activities, including identifying potential drug targets, selecting suitable therapeutic approaches, designing and optimising molecules, improving manufacturing reliability, preparing regulatory submissions, and planning and managing clinical trials.
Anthropic's strategy is to integrate AI into a wider range of these activities rather than focus on a single aspect of drug discovery. By working directly with organisations involved in real drug development programmes, the company aims to understand where AI can deliver meaningful improvements across different disease areas and stages of development.
The partnerships are expected to serve three objectives. First, they will help Anthropic assess Claude's capabilities and limitations across a broader range of scientific and operational tasks. Insights from the collaborations have already informed specific priorities for improving its AI models.
Second, the programmes are intended to provide practical examples for the wider life sciences industry, demonstrating how AI can be integrated into biotechnology research and drug development workflows. Anthropic said it plans to work with more biotechnology companies and deepen the integration of Claude into their development processes.
Third, the research could contribute directly to the development of new treatments. Anthropic said its ongoing programmes include work targeting food allergies, rare childhood diseases and several forms of cancer, with the potential to support the development of new medicines if the projects continue to progress positively.
The company has also indicated that Claude is handling a substantial share of the scientific and operational work in its internally initiated programmes for rare childhood forms of muscular dystrophy.
Anthropic plans to scale up its life sciences activities substantially. It has also shared technical reports outlining its approaches, methods and early findings from the ongoing collaborations, offering further insight into how AI systems could support research and development across the pharmaceutical and biotechnology sectors.
